Fresenius Sues InvaGen Over Generic PhosLo GelCaps

Law360, New York (September 16, 2011, 7:09 PM EDT) -- Fresenius Medical Care Holdings Inc. slapped InvaGen Pharmaceuticals Inc. with a patent infringement suit Friday in Massachusetts federal court in an effort to block it from marketing a generic version of PhosLo GelCaps.

Dialysis services provider Fresenius filed suit after InvaGen filed an abbreviated new drug application with the U.S. Food and Drug Administration to sell a generic form of PhosLo GelCaps, used in end-stage renal failure to boost calcium levels and combat high levels of phosphate in the blood, before Fresenius’ patent for the drug...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.